Kodiak Sciences Inc. cash flow to debt ratio of -85.44% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Kodiak Sciences Inc.'s free cash flow has decreased 15.97% from $-117.72M last year to $-136.51M, signaling decreasing performance

Kodiak Sciences Inc.'s debt to equity ratio is 1.39, which means that the company's assets are unhealthy financed, signaling financial risk.

Kodiak Sciences Inc.'s debt has increased relative to shareholder equity from 0.47 last year to 1.39 today, signaling weakened financials

Kodiak Sciences Inc. has a net cash position, so leverage is healthy.

Kodiak Sciences Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Kodiak Sciences Inc. has insufficient data to evaluate this check.

Kodiak Sciences Inc.'s short-term assets of $214.82M exceed its short-term liabilities of $45.53M

Kodiak Sciences Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Kodiak Sciences Inc.'s return on equity of -253.85%, is lower than 15.00%, indicating bad performance

Kodiak Sciences Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Kodiak Sciences Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Kodiak Sciences Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Kodiak Sciences Inc. has negative free cash flow, indicating cash burn

Kodiak Sciences Inc.'s yearly earnings has decreased 30.51% since last year from $-176.21M to $-229.97M, signaling decreasing performance

Kodiak Sciences Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -87.69% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Kodiak Sciences Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Kodiak Sciences Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Kodiak Sciences Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Kodiak Sciences Inc. has insufficient data to evaluate this check.

Kodiak Sciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kodiak Sciences Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Kodiak Sciences Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Kodiak Sciences Inc. has insufficient data to evaluate this check.

Kodiak Sciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kodiak Sciences Inc. has a price-to-book ratio of 23.95x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Kodiak Sciences Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue